Zimmer Biomet: Paragon 28 integration and debt paydown mask a 2026 EPS trough

Stevie AI on Zimmer Biomet Holdings, Inc. (ZBH-USA | zimmerbiomet)

10/27/2026

Summary

Zimmer Biomet is a top-three global orthopedic device maker, holding #1/#2 share positions in hips and knees worldwide, with a growing foot-and-ankle and extremities franchise following the Paragon 28 acquisition. The key structural insight is that FY2026 marks an earnings trough driven by elevated net interest expense from the debt-funded Paragon 28 deal and ongoing sales-force transformation costs, not a deterioration in the underlying franchise — Hips and S.E.T. are growing nicely, Knees softness is a share and transformation issue rather than a market one, and margins are set to recover mechanically as purchase accounting drag rolls off and debt gets paid down from $6.5B toward $4.3B by FY2029. FY2025 actuals show revenue growing to $8.2B from $7.7B, but net income fell from $0.9B to $0.7B and EPS dropped from $4.43 to $3.55, reflecting the cost of the Paragon 28 acquisition and transformation investment. FY2026 guidance (raised organic cc growth to 2.25-3.25%, adjusted EPS of $8.47-8.59 on an adjusted basis, though our GAAP-comparable forecast EPS is $3.92) and 9-11% FCF growth indicate the company is executing through this trough with better-than-feared disruption from the sales force transformation. Free cash flow of $1.6B in FY2026 growing to $1.9B by FY2029, alongside continued buybacks under the newly expanded $1.0B authorization, provides the mechanism for EPS to more than double from $3.92 in FY2026 to $8.64 by FY2029. We apply a 14x forward P/E multiple, below the medical device large-cap peer average (Stryker and J&J MedTech typically trade 18-22x), reflecting ZBH's slower organic growth profile, residual integration risk, and leverage overhang, but above a value-trap multiple given the credible EPS recovery path. Anchoring on FY2027 as the first fully normalized earnings year ($6.22 EPS x 14x = $87.08), we discount back to FY2026 ($79.16) given the transitional nature of that year's earnings, and apply the multiple directly to FY2028 ($102.62) and FY2029 ($120.96) as margin and leverage normalize. This implies meaningful upside from the current $97.44 price by FY2028-2029, though FY2026-2027 targets sit near or modestly below the current price, suggesting patience is required for the thesis to play out.

Thesis

1. **Trough earnings year, not trough franchise.** FY2026's EPS of $3.92 looks weak against FY2024's $4.43, but this is an artifact of financing costs and integration drag, not operating deterioration. Net interest expense of ~$295M reflects the debt raised for Paragon 28, and this expense mechanically declines as net debt falls from $6.5B in FY2026 to $4.3B by FY2029. Meanwhile revenue is still growing (+4.4% reported in FY2026, accelerating organic cc guidance to 2.25-3.25%), meaning the earnings weakness is a capital structure and transition story that resolves on its own timeline rather than a demand problem. 2. **Paragon 28 and S.E.T. provide the growth engine Knees can no longer supply.** Knees has been the historical largest category but is now under share pressure amid the sales-force transformation. Paragon 28 contributes roughly 110 basis points to FY2026 reported growth and extends ZBH into foot-and-ankle, a faster-growing extremities niche with less direct head-to-head competition from Stryker and J&J's core recon lines. Hips was called out as the strongest performer in the most recent quarter, evidence that the recon franchise overall remains competitive even as Knees lags. 3. **Margin recovery is mechanical, not speculative.** Gross margin is guided to ~71% in FY2026, down 120 basis points year over year, driven by purchase accounting step-up costs tied to Paragon 28 and input cost inflation. This drag is a known, finite accounting artifact that normalizes over the following 1-2 years. Operating margin is expected down only slightly more than 50 basis points from the FY2025 baseline despite continued R&D investment in robotics (ROSA, ROSA Shoulder) and Paragon 28 integration costs, suggesting underlying SG&A leverage is already offsetting much of the investment spend. 4. **Free cash flow conversion and buybacks compound EPS growth well ahead of net income growth.** FCF is guided to grow 9-11% in FY2026 to $1.6B, rising to $1.9B by FY2029, even as net income growth is more modest in percentage terms in the earlier years. Combined with the expanded $1.0B buyback authorization ($500M already executed in H1 2026), this creates a wedge between net income growth and EPS growth — net income roughly 1.7x from FY2026 to FY2029 ($0.7B to $1.2B) while EPS grows 2.2x ($3.92 to $8.64) over the same period, a function of both margin recovery and consistent share count reduction. 5. **The market is pricing ZBH as a structurally challenged recon player, not as a company mid-transformation.** At $97.44, the stock trades at roughly 25x FY2026 EPS of $3.92 but only about 11x FY2029 EPS of $8.64 — a multiple compression that only makes sense if the market believes the EPS recovery path will not materialize. Given that FCF growth, debt paydown, and buyback mechanics are already visible in FY2026 guidance (not speculative future assumptions), we think the market is overweighting near-term transformation disruption risk and underweighting the clear, guided path to margin and EPS normalization. 6. **Catalysts are near-term and verifiable.** The Q3 2026 earnings call (November 4, 2026) offers a checkpoint on Technology/robotics momentum, ROSA Shoulder ramp, and whether Knees stabilizes. Separately, the anticipated Monogram 510(k) filing represents an option on next-generation robotics-enabled personalized implants, a call option not currently reflected in consensus numbers given its early stage. Each successive quarter of 'less disruption than expected' commentary from management should incrementally de-risk the sales-force transformation thesis and support multiple re-rating toward peer averages.

Risks

1. **U.S. Sales Force Transformation Execution Risk.** The multi-year sales force transformation, while described by management as experiencing less disruption than expected, carries real execution risk as Stage 2 is accelerated. Competitive poaching of reps by Stryker or J&J MedTech during the transition window, loss of surgeon relationships, and uneven regional performance could extend or deepen the Knees share erosion beyond current guidance assumptions. 2. **Leverage and interest rate sensitivity.** Net debt of $6.5B in FY2026 following the debt-funded Paragon 28 acquisition leaves ZBH more exposed to interest rate moves and refinancing risk than less-levered peers. The EPS recovery thesis is partly contingent on successful and timely debt paydown to $4.3B by FY2029; any disruption to free cash flow generation (procedure volume softness, pricing pressure, or integration cost overruns) would slow deleveraging and prolong the interest expense drag on earnings. 3. **Pricing erosion in a mature, share-driven market.** Management's own guidance assumes flat to 100 basis points of pricing erosion for FY2026, with Q2 already showing an 80 basis point headwind. Recon and trauma markets are mature with limited volume expansion outside the 4-5% procedural growth backdrop, meaning ZBH's growth is overwhelmingly share-driven in a market where Stryker and J&J MedTech compete aggressively on price and technology, risking further margin compression if pricing pressure intensifies beyond guided ranges. 4. **International and China exposure.** Guidance explicitly flags China weakness, emerging market softness, and geopolitical/tender dynamics as headwinds. Volume-based procurement (VBP) tender risk in China has historically pressured device pricing sharply, and any acceleration of these dynamics could weigh on international segment growth beyond what is embedded in the 2.25-3.25% organic constant currency guidance. 5. **Paragon 28 integration risk.** While Paragon 28 is expected to contribute meaningfully to growth and diversify ZBH into foot-and-ankle, integration risk remains — cultural fit, sales channel conflicts with the broader S.E.T. salesforce, and the ability to sustain Paragon 28's pre-acquisition growth rate inside a larger, more bureaucratic organization are unproven. A slower-than-expected integration could delay the gross margin normalization currently baked into the ~71% guidance. 6. **Multiple re-rating is not guaranteed even if fundamentals recover.** Our price targets assume the market eventually applies a 14x multiple to normalized EPS; however, if ZBH's growth profile continues to lag Stryker and J&J MedTech structurally (given its slower organic cc growth guidance versus peers' typically higher growth algorithms), the market may continue to assign a discount multiple even after earnings recover, capping upside relative to our price targets regardless of EPS delivery.

📈 Price Targets